Gelteq (GELS) Stock Price, News & Analysis

Company Overview

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Key Stats

• Today's Range: $0.45 to $0.51
• 50-Day Range: $0.45 to $0.80
• 52-Week Range: $0.44 to $3.51
• Volume: 46,791 shs
• Average Volume: 714,634 shs
• Market Capitalization: $4.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Gelteq Stock Analysis - MarketRank™

Gelteq scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Gelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Gelteq has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Gelteq has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.53% of the float of Gelteq has been sold short.

Short Interest Ratio / Days to Cover

Gelteq has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gelteq has recently decreased by 21.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gelteq does not currently pay a dividend.

Dividend Growth

Gelteq does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Gelteq this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gelteq insiders have not sold or bought any company stock.

Percentage Held by Institutions

Gelteq has minimal institutional ownership at this time.

GELS Stock Analysis - Frequently Asked Questions

How have GELS shares performed this year?

Gelteq's stock was trading at $0.80 at the beginning of the year. Since then, GELS shares have decreased by 41.9% and is now trading at $0.4650.

When did Gelteq IPO?

Gelteq (GELS) raised $5 million in an initial public offering (IPO) on Tuesday, October 29th 2024. The company issued 1,300,000 shares at a price of $4.00 per share. The Benchmark Company served as the underwriter for the IPO.

How do I buy shares of Gelteq?

Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/07/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GELS
• Previous Symbol: NASDAQ:GELS
• CIK: 1920092
• Web: www.gelteq.com
• Phone: 61-3-9087-3990
• Fax: N/A
• Employees: N/A
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $110 thousand
• Price / Sales: 44.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 10,710,000
• Free Float: N/A
• Market Cap: $4.89 million
• Optionable: N/A
• Beta: 0.06